The RECONNOITER Study is a 76 patient prospective, double-blind, randomized Phase 2A trial designed to assess the safety and efficacy of cilnidipine alone and in combination with tadalafil in patients with scleroderma and secondary Raynaud’s. The study will assess the impact of the treatments on a variety of endpoints including Raynaud symptoms, GI effects, endothelial dysfunction and overall assessments of well-being. The study is being conducted in two parts, Part A, a Phase 2A parallel arm design to evaluate dose, safety, and efficacy and Part B a Phase 2 randomized crossover design to formally demonstrate safety and efficacy.

Patients are being recruited at two hospitals in Australia, and the study started in June of 2021. Following this study, a United States multicenter study is planned. On July 25, 2022, the Data Safety Monitoring Board (DSMB) for the study met and reviewed data on the first 27 patients in part A and selected a dose of Profervia® to be used in the second part of the study and felt that the first part of the study had met all of its goals so voted to terminate enrollment of the additional 9 patients and end that part of the study early. The DSMB felt that the drug was well tolerated, the study design was robust, and that a strong suggestion of efficacy had been demonstrated. Aisa will begin its second part of RECONNOITER-1 in the 3rd quarter of 2022.

Scleroderma, or systemic sclerosis, is a devastating autoimmune disease with the highest mortality and disability incidences of this group of diseases. While treatments have been approved to treat the lung changes that accompany the disease, there is no treatment approved to treat the Raynaud symptoms that occur in 95% of these patients, the GI symptoms, or significantly modify the course of the disease. It is hoped that the combination of these two drugs, called PROFERVIA^®, may produce such as result.